Proactive Investors - Run By Investors For Investors

Two US approvals spell big business potential for Circassia

Circassia Pharmaceuticals PLC (LON:CIR) is a company focussed on treating patients with respiratory diseases which has just won two new significant US approvals.The approvals could unlock hundreds of millions of dollars of potential market share which could transform the business. Circassia CEO Steve Harris tells Proactive London how the products fit into the rest of the portfolio and why this hurdle is also important for patients suffering from COPD and CHD.
Circassia has several other asthma and COPD treatments in its pipeline including  AirNOvent – a portable system that uses electricity to make nitric oxide in turn to dilate blood vessels in the lungs.

Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use